Chemokine (C-X-C Motif) receptor 4 blockade by AMD3100 inhibits experimental abdominal aortic aneurysm expansion through anti-inflammatory effects

Arteriosclerosis, Thrombosis, and Vascular Biology

Volumn 34, Issue 8, 2014, Pages 1747-1755

  Michineau, Stéphanie ^a   Franck, Grégory ^a   Wagner Ballon, Orianne ^b   Dai, Jianping ^a   Allaire, Eric ^a   Gervais, Marianne ^a  

^a FACULTÉ DE MÉDECINE   (France)

^b HENRI MONDOR HOSPITAL   (France)

Author keywords

Abdominal; Aortic aneurysm; Chemokine CXCL12; Inflammation; Pharmacology

Indexed keywords

AORTIC ANEURYSM, ABDOMINAL; CHEMOKINE CXCL12; INFLAMMATION; PHARMACOLOGY;

ANIMALS; ANTI-INFLAMMATORY AGENTS; AORTA, ABDOMINAL; AORTIC ANEURYSM, ABDOMINAL; BONE MARROW TRANSPLANTATION; CALCIUM CHLORIDE; CHEMOKINE CXCL12; CHEMOTAXIS; DISEASE MODELS, ANIMAL; GREEN FLUORESCENT PROTEINS; GUINEA PIGS; HETEROCYCLIC COMPOUNDS; HETEROGRAFTS; HUMANS; INFLAMMATION MEDIATORS; MACROPHAGES; MALE; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; MYOCYTES, SMOOTH MUSCLE; RATS; RATS, INBRED F344; RECEPTORS, CXCR4; TIME FACTORS; U937 CELLS;

EID: 84904598505     PISSN: 10795642     EISSN: 15244636     Source Type: Journal    
DOI: 10.1161/ATVBAHA.114.303913     Document Type: Article

References (42)

1. Sakalihasan N, Limet R, Defawe OD. Abdominal aortic aneurysm. Lancet. 2005;365:1577-1589.
2. Michel JB, Martin-Ventura JL, Egido J, Sakalihasan N, Treska V, Lindholt J, Allaire E, Thorsteinsdottir U, Cockerill G, Swedenborg J. Novel aspects of the pathog enesis of aneurysms of the abdominal aorta in humans. Cardiovasc Res. 2011;90:18-27.
3. Kazi M, Zhu C, Roy J, Paulsson-Berne G, Hamsten A, Swedenborg J, Hedin U, Eriksson P. Difference in matrix-degrading protease expression and activity between thrombus-free and thrombus-covered wall of abdominal aortic aneurysm. Arterioscler Thromb Vasc Biol. 2005;25:1341-1346.
4. Aiuti A, Webb IJ, Bleul C, Sp ringer T, Gutierrez-Ramos JC. The chemokine SDF-1 is a chemoattractant for human CD34+ hematopoietic progenitor cells and provides a new mechanism to explain the mobilization of CD34+ progenitors to peripheral blood. J Exp Med. 1997;185:111-120.
5. Bleul CC, Fuhlbrigge RC, Casasnovas JM, Aiuti A, Springer TA. A highly efficacious lymphocyte chemoattractant, stromal cell-derived factor 1 (SDF-1). J Exp Med. 1996;184:1101-1109.
6. De Klerck B, Geboes L, Hatse S, Kelchtermans H, Meyvis Y, Vermeire K, Bridger G, Billiau A, Schols D, Matthys P. Pro-inflammatory properties of stromal cell-derived factor-1 (CXCL12) in collagen-i nduced arthritis. Arthritis Res Ther. 2005;7:R1208-R1220.
7. Wang A, Fairhurst AM, Tus K, Subramanian S, Liu Y, Lin F, Igarashi P, Zhou XJ, Batteux F, Wong D, Wakeland EK, Mohan C. CXCR4/CXCL12 hyperexpression plays a pivotal role in the pathogenesis of lupus. J Immunol. 2009;182:4448-4458.
8. Gonzalo JA, Lloyd CM, Peled A, Delaney T, Coyle AJ, Gutierrez-Ramos JC. Cri tical involvement of the chemotactic axis CXCR4/stromal cellderived factor-1 alpha in the inflammatory component of allergic airway disease. J Immunol. 2000;165:499-508.
9. Negrete-García MC, Velazquez JR, P opoca-Coyotl A, Montes-Vizuet AR, Juárez-Carvajal E, Teran LM. Chemokine (C-X-C motif) ligand 12/ stromal cell-derived factor-1 is associated with leukocyte recruitment in asthma. Chest. 2010;138:100-106.
10. Werner L, Guzner-Gur H, Dotan I. Involvement of CXCR4/CXCR7/CXCL12 Interactions in Inflammatory bowel disease. Theranostics. 2013;3:40-46.
11. Lukacs NW, Berlin A, Schols D, Skerlj RT, Bridger GJ. AMD3100, a CxCR4 antagonist, attenuates allergic lung inflammation and airway hyperreactivity. Am J Pathol. 2002;160:1353-1360.
12. Xia XM, Wang FY, Xu WA, Wang ZK, Liu J, Lu YK, Jin XX, Lu H, Shen YZ. CXCR4 antagonist AMD3100 attenuates colonic damage in mice with experimental colitis. World J Gastroenterol. 2010;16:2873-2880.
13. Parietti E, Pallandre JR, Deschaseaux F, A upècle B, Durst C, Kantelip JP, Chocron S, Davani S. Presence of circulating endothelial progenitor cells and levels of stromal-derived factor-1α are associated with ascending aorta aneurysm size. Eur J Cardiothorac Surg. 2011;40:e6-12.
14. Ocaña E, Pérez-Requena J, Bohórquez JC, Brieva JA, Rodríguez C. Chemokine receptor expression on infiltrating lymphocytes from abdominal aortic aneurysms: role of CXCR4-CXCL12 in lymphoid recruitment. Atherosclerosis. 2008;200:264-270.
15. Dai J, Michineau S, Franck G, Desgranges P, Becquemin JP, Gervais M, Allaire E. Long term stabilization of expanding aortic aneurysms by a short course of cyclosporine A through transforming growth factor-beta inducti on. PLoS One. 2011;6:e28903.
16. Allaire E, Schneider F, Saucy F, Dai J, Cochennec F, Michineau S, Zidi M, Becquemin JP, Kirsch M, Gervais M. New insight in aetiopathogenesis of aortic diseases. Eur J Vasc Endovasc Surg. 2009;37:531-537.
17. Allaire E, Forough R, Clowes M, Starcher B, Clowes AW. Local overexpression of TIMP-1 prevents aortic aneurysm degeneration and rupture in a rat model. J Clin Invest. 1998;102:1413-1420.
18. Allaire E, Hasenstab D, Kenagy RD, Starcher B, Clowes MM, Clowes AW. Prevention of aneurysm development and rupture by local overexpression of plasminogen activator inhibitor-1. Circulation. 1998;98:249-255.
19. Sanchez-Martin L, Sanchez-Mateos P, Cabanas C. CXCR7 impact on CXCL12 biology and disease. Trends Mol Med. 2012;19:12-22.
20. Janowski M. Functional diversity of SDF-1 splicing variants. Cell Adh Migr. 2009;3:243-249.
21. Moehle CW, Bhamidipati CM, Alexander MR, Mehta GS, Irvine JN, Salmon M, Upchurch GR J r, Kron IL, Owens GK, Ailawadi G. Bone marrow-derived MCP1 required for experimental aortic aneurysm formation and smooth muscle phenotypic modulation. J Thorac Cardiovasc Surg. 2011;142:1567-1574.
22. Iid a Y, Xu B, Xuan H, Glover KJ, Tanaka H, Hu X, Fujimura N, Wang W, Schultz JR, Turner CR, Dalman RL. Peptide inhibitor of CXCL4-CCL5 heterodimer formation, MKEY, inhibits experimental aortic aneurysm initiation and progression. Arterioscler Thromb Vasc Biol. 2013;33:718-726.
23. Johnston WF, Salmon M, Su G, Lu G, Stone ML, Zhao Y, Owens GK, Upchurch GR Jr, Ailawadi G. Genetic and pharmacologic disruption of interleukin-1β signaling inhibits experimental aortic aneurysm formation. Arterioscler Thromb Vasc Biol. 2013;33:294-304.
24. Harrison SC, Smith AJ, Jones GT, et al. Interleukin-6 receptor pathways in abdominal aortic aneurysm. Eur Heart J. 2013;34(48):3707-3716.
25. Xiong W, MacTaggart J, Knispel R, Worth J, Persidsky Y, Baxter BT. Blocking TNF-alpha attenuates aneurysm formation in a murine model. J Immunol. 2009;183:2741-2746.
26. Middleton RK, Lloyd GM, Bown MJ, Cooper NJ, London NJ, Sayers RD. The pro-inflammatory and chemotactic cytokine microenvironment of the abdomin al aortic aneurysm wall: a protein array study. J Vasc Surg. 2007;45:574-580.
27. Barthel SR, Gavino JD, Descheny L, Dimitroff CJ. Targeting selectins and selectin ligands in inflammation and cancer. Expert Opin Ther Targets. 2007;11:1473-1491.
28. Theruvath TP, Jones JA, Ikonomidis JS. Matrix metalloproteinases and descending aortic aneurysms: parity, disparity, and switch. J Card Surg. 2012;27:81-90.
29. McCormick ML, Gavrila D, Weintraub NL. Role of oxidative stress in the pathogenesis of abdominal aortic aneurysms. Arterioscler Thromb Vasc Biol. 2007;27:461-469.
30. Zhang J, Schmidt J, Ryschich E, Mueller-Schilling M, Schumacher H, Allenberg JR. Inducible nitric oxide synthase is present in human abdominal aortic aneurysm and promotes oxidative vascular injury. J Vasc Surg. 2003;38:360-367.
31. Holmes DR, Liao S, Parks WC, Thompson RW. Medial neovascularization in abdominal aortic aneurysms: a histopathologic marker of aneurysmal degeneration with pathophysiologic implications. J Vasc Surg. 1995;21:761-71; discussion 771.
32. Choke E, Cockerill GW, Dawson J, Howe F, Wilson WR, Loftus IM, Thompson MM. Vascular endothelial growth factor enhances angiotensin II-induced aneurysm f ormation in apolipoprotein E-deficient mice. J Vasc Surg. 2010;52:159-166.e1.
33. Baxter BT, Terrin MC, Dalman RL. Medical management of small abdominal aortic aneurysms. Circulation. 2008;117: 1883-1889.
34. Brady AR, Thompson SG, Fowkes FG, Greenhalgh RM, Powell JT. Abdominal aortic aneurysm expansion: risk factors and time intervals for surveillance. Circulation. 2004;110:16-21.
35. Allaire E., Muscatelli-Groux B, Guinault A.M., Pages C., Goussard A., Mandet C., Bruneval P., Méllière D., Becquemin JP. Vascular smooth muscle cell endovascular therapy stabilizes already developed aneurysm s in a model of aortic injury elicited by inflammation and proteolysis, Ann Surg. 2004, 239, 417-427.
36. Franck G, Dai J, Fifre A, Ngo S, Justine C, Michineau S, Allaire E, Gervais M. Reestabl ishment of the endothelial lining by endothelial cell therapy stabilizes experimental abdominal aortic aneurysms. Circulation. 2013;127:1877 -1887.
37. Schneider F, Saucy F, de Blic R, Dai J, Mohand F, Rouard H, Ricco JB, Becquemin JP, Gervais M, Allaire E. Bone marrow mesenchymal stem cells stabilize already-formed aortic aneurysms more efficiently than vascular smooth muscle cells in a rat model. Eur J Vasc Endovasc Surg. 2013;45:666-672.
38. Dai J, Losy F, Guinault AM, Pages C, Anegon I, Desgranges P, Becquemin JP, Allaire E. Overexpression of transforming growth factor-beta1 stabilizes already-formed aortic aneu rysms: a first approach to induction of functional healing by endovascular gene therapy. Circulation. 2005;112:1008-1015.
39. Dugan MJ, Maziarz RT, Bensinger WI, Nademanee A, Liesveld J, Badel K, Deh ner C, Gibney C, Bridger G, Calandra G. Safety and preliminary efficacy of plerixafor (Mozobil) in combination with chemotherapy and G-CSF: an open-label, multicenter, exploratory trial in patients with multiple myeloma and non-Hodgkin 's lymphoma undergoing stem cell mobilization. Bone Marrow Transplant. 2010;45:39-47.
40. McDermott DH, Liu Q, Velez D, et al. A phase 1 clinical trial of longterm, low-dose treatment of WHIM syndrome with the CXCR4 antagonist plerixafor. Blood. 2014;123(15):2308-2316.
41. Hattori K, Heissig B, Tashiro K, Honjo T, Tateno M, Shieh JH, Hackett NR, Quitoriano MS, Crystal RG, Rafii S, Moore M A. Plasma elevation of stromal cell-derived factor-1 induces mobilization of mature and immature hematopoietic progenitor and stem cells. Blood. 2001;97:3354-3360.
42. Lapidot T, Dar A, Kollet O. How do stem cells find their way home? Blood. 2005;106:1901-1910.